Core Viewpoint - Tarsus Pharmaceuticals has appointed David E. I. Pyott, a prominent figure in the biopharmaceutical industry and former CEO of Allergan, to its Board of Directors, which is expected to enhance the company's growth and innovation in eye care and other therapeutic areas [1][2][10]. Company Overview - Tarsus Pharmaceuticals focuses on revolutionizing treatment for patients, particularly in eye care, and is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including dermatology and infectious disease prevention [5]. Leadership Experience - David E. I. Pyott has over 17 years of experience as CEO of Allergan, where he grew the company from approximately $1 billion in sales to over $7 billion in revenue, demonstrating a strong ability to navigate market complexities while maintaining a focus on long-term growth [2][3]. - Pyott has also held significant roles at Novartis and has been recognized as one of Harvard Business Review's "100 Best Performing CEOs in the World" [2]. Strategic Vision - Pyott expressed enthusiasm about joining Tarsus at a pivotal time, highlighting the company's strong foundation with its lead product and promising pipeline, and his commitment to building long-term value and advancing innovation in eye care [3]. Current Developments - Tarsus's lead commercial product, XDEMVY (lotilaner ophthalmic solution) 0.25%, is FDA approved for treating Demodex blepharitis, and the company is also developing additional treatments, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both currently in Phase 2 trials [5].

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About ...

Core Insights - Tarsus Pharmaceuticals will present data on the global prevalence and patient burden of Demodex blepharitis, along with the efficacy of XDEMVY at the ASCRS 2025 Annual Meeting [1][2] Group 1: Demodex Blepharitis - Demodex blepharitis is a common eyelid disease caused by Demodex mites, affecting over two-thirds of blepharitis cases and potentially impacting 25 million Americans [7] - The Titan study indicates that 58% of patients visiting U.S. eye care clinics show signs of Demodex mite infestation, with 45 million annual visits to eye care clinics [7] Group 2: XDEMVY (Lotilaner Ophthalmic Solution) - XDEMVY is a novel prescription eye drop designed to treat Demodex blepharitis by targeting the underlying mite infestation [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with statistical significance and no serious treatment-related adverse events [8][9] - The most common side effect reported was stinging and burning in 10% of patients, while other adverse reactions were less than 2% [9][11] Group 3: Upcoming Presentations - The ASCRS meeting will feature several presentations, including: - A longitudinal evaluation of disease burden and treatment efficacy in patients with Demodex blepharitis [3] - A study assessing specific symptoms of Demodex blepharitis [4] - Research on the treatment of Demodex blepharitis in patients with Meibomian gland dysfunction [5] - An observational study on the prevalence of Demodex blepharitis in Japan [6]